Amylin Pharmaceuticals, Inc.
3 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 7 name spellings.
6
Ending by 2030
Aug 2027
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Apr 20, 2027The maintenance fee for GLP-1 receptor agonists for islet cell transplantation (US 9,161,953) comes due Apr 20, 2027. Unpaid by Oct 20, 2027, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Showing 1 to 8 of 8
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,076,288 | Hybrid polypeptides having glucose lowering activity In force · From the USPTO record | In force | From the USPTO record | |
| US 8,263,545 | GIP analog and hybrid polypeptides with selectable properties In force · From the USPTO record | In force | From the USPTO record | |
| US 8,389,472 | EXENDIN-4 to Treat Nonalcoholic Steatohepatitis and Nonalcoholic Fatty Liver Disease In force · High confidence | In force | High confidence | |
| US 8,497,240 | DPP-IV Resistant GIP Hybrid Polypeptides with Selectable Properties In force · Medium confidence | In force | Medium confidence | |
| US 8,946,149 | Use of Exendin and Analogs Thereof To Delay or Prevent Cardiac Remodeling In force · High confidence | In force | High confidence | |
| US 8,895,033 | Sustained Release Formulations Using Non-Aqueous Carriers In force · High confidence | In force | High confidence | |
| US 9,161,953 | GLP-1 receptor agonists for islet cell transplantation In force · From the USPTO record | In force | From the USPTO record | |
| US 9,382,304 | Engineered polypeptides having enhanced duration of action with reduced immunogenicity In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 8: 3 patents in force now held by others · 94 lapsed for an unpaid fee · 84 ended at full term · 1 surrendered on reissue. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
20 abandoned · 64 no status recorded